CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Oxygen gasWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug1210 Inhaled nitric oxide (iNO) Wiki 1.00
drug1609 Nitrogen gas Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D000860 Hypoxia NIH 0.23

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0012418 Hypoxemia HPO 0.23

There is one clinical trial.

Clinical Trials

1 Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen

This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.

NCT04398290 COVID-19 Hypoxemia Hypoxemic Respiratory Failure Drug: Inhaled nitric oxide (iNO) Drug: Nitrogen gas Drug: Oxygen gas
MeSH:Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: As assessed per treating physician's discretion.

Measure: Incidence of treatment emergent adverse events

Time: Up to 14 days

Description: Incidence of hypoxemia and hypotension as assessed per treating physician's discretion.

Measure: Incidence of adverse events

Time: Up to 6 hours

Description: Incidence of increase to > 5% total methemoglobin as assessed by pulse oximetry.

Measure: Incidence of methemoglobinemia

Time: Up to 14 days

Secondary Outcomes

Description: Worsening respiratory status as defined by any one of the following: Implementation of High Flow Nasal Cannula (HFNC), non-rebreather mask, non-invasive ventilation, intubation and mechanical ventilation or need for intubation (in the event the patient is not intubated due to do not intubate (DNI) or do not resuscitate (DNR) status).

Measure: Number of participants with progression of respiratory failure

Time: Up to 14 days

Description: The number of days until hypoxemia is resolved as per treating physician assessment

Measure: Time until resolution of hypoxemia

Time: Up to 14 days

Description: Incidence of death during hospitalization and after discharge up to 28 days

Measure: Incidence of mortality

Time: Up to 28 days

Description: Number of days of hospitalization

Measure: Duration of hospitalization

Time: Up to 28 days

Related HPO nodes (Using clinical trials)

HP:0012418: Hypoxemia
Genes 14
GATA6 GDNF HBB SLC35A1 ASCL1 ZFPM2 EDN3 HBB RET PHOX2B CSF2RA FBN1 FGFR3 CSF2RB
Protein Mutations 2
P317R R200W
SNP 0